Portfolio 5 - Multicentre Dietary Advice on Serum Lipids in Hyperlipidemia
|First Received Date ICMJE||February 21, 2007|
|Last Updated Date||December 3, 2015|
|Start Date ICMJE||January 2007|
|Primary Completion Date||January 2011 (final data collection date for primary outcome measure)|
|Current Primary Outcome Measures ICMJE
||Primary Outcome Measures Described Below [ Time Frame: December 2011 ] [ Designated as safety issue: No ]
Plasma LDL-C concentrations
|Original Primary Outcome Measures ICMJE||Not Provided|
|Change History||Complete list of historical versions of study NCT00438425 on ClinicalTrials.gov Archive Site|
|Current Secondary Outcome Measures ICMJE
||Secondary Outcome Measures Described Below [ Time Frame: January 2016 (anticipated) ] [ Designated as safety issue: No ]
Total-C:HDL-C ratio, total-C, triglycerides, HDL-C, apolipoproteins A-1 and B, LDL particle size, oxidized LDL (conjugated dienes), Lp(a), homocysteine, C-reactive protein, glucose and insulin, waist circumference, blood pressure, diet records focusing on the intake of saturated fat and the amounts of the four key dietary components of the portfolio diet (viscous fibers, soy proteins, plant sterols, and almonds). Urinary urea, creatinine, and minerals.
|Original Secondary Outcome Measures ICMJE||Not Provided|
|Current Other Outcome Measures ICMJE
||Tertiary Outcome Measures Described Below [ Time Frame: January 2016 (anticipated) ] [ Designated as safety issue: No ]
Plasma and red cell membrane sterols and red cell membrane sterols and red cell membrane integrity (erythrocyte fragility).
|Original Other Outcome Measures ICMJE||Not Provided|
|Brief Title ICMJE||Portfolio 5 - Multicentre Dietary Advice on Serum Lipids in Hyperlipidemia|
|Official Title ICMJE||Assessment of the Practical Application, Acceptability and Effectiveness of a Portfolio Diet in Reducing Serum Cholesterol|
The purpose of this trial is to re-evaluate the potential role of diet in modulating cardiovascular risk factors. If potent lipid-lowering effects through novel dietary interventions can be demonstrated, then diet may again be seen as providing an alternative to drug therapy in the primary prevention of cardiovascular disease.
This is a randomized parallel study with three experimental arms of 6 months duration to estimate the effect of the portfolio diet under real world conditions at two levels of advice intensity. Every effort will be made to obtain study blood samples and other data from all subjects at the designated times regardless of compliance with the dietary aspects of the study protocol. All subjects will be used in the intent-to-treat analysis.
Four Canadian Centers will be involved: Vancouver, Toronto, Manitoba and Quebec City. The study will be partially blinded. The investigators and technical staff will be blinded but the dietitians and the patients will not be, owing to the differences in taste and appearance of the study foods. The blinding of physicians at clinic visits is likely to be difficult due to the requirement to ask questions related to diet. All patients referred to the four collaborating clinics will be asked whether they would be prepared to modify their diet if that may mean they might lower their blood cholesterol without the use of drugs. Those who checked the box for "No" or "only modest dietary change" would not be considered further. Those who checked the box for "significant" or "radical dietary change" would be invited to participate, providing they are not at high risk (<20% 10 yr risk) of CHD and were within 30% of their target LDL-C concentrations according to current Canadian Working Group recommendations i.e., those who would normally be considered for a preliminary test of diet. The three groups would be randomized to either a low saturated fat, low cholesterol diet (Step 2) or a portfolio diet both given as routine clinical advice at week zero with follow up at 3 and 6 months or more intensive advice reinforced (intensive portfolio) at clinic visits at 2, 4, 8, 12, 16 and 20 weeks. In the routine portfolio, the advice will therefore consist of two half hour sessions with the dietitian (0 and 12 weeks), compared to seven for the intensive portfolio (0, 2, 4, 8, 12, 16 and 20 weeks). Prior to starting each diet the nature of the diet will be explained to the participants and instruction on achieving diet goals will be given. Follow-up visits will be used to go over the subjects' diet record, which they have recorded over the previous 7 days, and reinforce the original dietary advice. The intensive portfolio participants will therefore receive five additional instructional and assessment follow up visits during the course of the study.
Trial treatments: The portfolio dietary advice will conform to current therapeutic diets appropriate for hypercholesterolemic subjects (<7% of energy saturated fat, <200 mg/d cholesterol) plus the combination of viscous fibers, soy protein, plant sterols and almonds. The portfolio diet plan will include foods which contribute 8 g/1000 kcal viscous fiber as β-glucan (oats, barley, oat bran breads and soups) and psyllium (cereal), 1 g plant sterol/1000 kcal diet (in sterol margarine), 22 g soy protein/1000 kcal (soy burgers, dogs, links, other meat analogues, milks, yogurts and cheese) and 22 g almonds/1000 kcal. The Step 2 therapeutic diet will encourage a similar macronutrient profile through the use of cereal fibers and whole grains. All diets will emphasize fruit and vegetable intakes (5-10 servings/d) according to current recommendations. Participants will be instructed on how to select and follow these diets and will be provided with only the margarine component of the portfolio and Step 2 therapeutic diets. The Step 2 therapeutic diet group will be encouraged to follow a diet of whole grain foods (brown rice, whole wheat breads, muffins and breakfast cereals), low saturated fat meat and dairy foods with a control margarine. The degree to which the portfolio diet can be made effective after routine instruction compared to more intensive instruction is the key issue in this study.
Duration of Subject participation and sequence and duration of all trial periods: Subject participation will start with the screening visit followed by a week minus 2 visit 4 to 6 weeks later. The week minus 2 visit will be followed by week 0 visit. Study duration is for 6 months, after which participants have the option of continuing for another 6 months.
Diets will be self-selected, low-fat, low-cholesterol, NCEP Step 2 diets (<7% saturated fats, <200 mg dietary cholesterol/d). The test and control margarines will be provided free. The oat bran bread will be provided at cost. The control diet will encourage a low saturated fat intake (<7%) by the use of low fat dairy products and egg substitutes (Fleischmann's egg beaters). Fiber will be increased to 17 g/1000 kcal recommending insoluble cereal fiber and whole meal or whole grain flour cereal products which are lipid neutral but conform to current diet guidelines for fiber intake and appear to offer protection from CHD. This will ensure equal total fiber intake on the NCEP and Portfolio diet. The control margarine (45 g/d) will have the same fatty acid composition as the test margarine. The Portfolio treatment diet will have a similar fatty acid and macronutrient profile to the control treatment diet. Low-fat Dairy and egg protein sources will be replaced with soy (approximately 45 g/d) protein. Foods will include soy dairy foods (milks, yogurts & cheese), and meat analogues made from soy isolate (dogs and burgers etc) and tofu products. The fiber will include at least 15 g viscous fiber daily from oats, barley, dried beans, peas, lentils and psyllium cereal. Plant sterols (1g/1000 kcal diet) up to 3g/day will be recommended from the test margarine provided which will be consumed up to a quantity of 40 g/day. A control margarine in the same quantity (25-40 g/d) will be provided to the participants in the control group. Almonds (22g/1000 kcal), the FDA recommended dose for cholesterol reduction) will also be included in the diet. The protein and fiber components will be individualized as much as possible to achieve study goals while satisfying individual preferences. The portfolio diet will be prescribed at two levels of reinforcement. In one portfolio cohort, the advice will be general and provided on 2 occasions over a 6 month period. For the second portfolio cohort, the advice will be much more intensive and provided on 7 occasions (total of 8 visits) over a 6 month period. Participants in the control and less intensive portfolio treatment groups will be seen at weeks 0, 12, 24 and optionally at 36 and 52 weeks. While participants in the intensive portfolio treatment group will be seen at two-weekly intervals for the first month and then monthly for the next five months (with a final visit at 6 months) and at two monthly intervals thereafter (if study is extended to 12 months) to ensure the diet plan is acceptable. Participants, in the intensive advice group, will be provided with self-taring scales on which to weigh all food to be consumed.
|Study Type ICMJE||Interventional|
|Study Phase||Phase 2|
|Study Design ICMJE||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Treatment
|Study Arm (s)||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
|Recruitment Status ICMJE||Active, not recruiting|
|Estimated Completion Date||January 2016|
|Primary Completion Date||January 2011 (final data collection date for primary outcome measure)|
|Eligibility Criteria ICMJE||
|Ages||21 Years to 100 Years (Adult, Senior)|
|Accepts Healthy Volunteers||No|
|Contacts ICMJE||Contact information is only displayed when the study is recruiting subjects|
|Listed Location Countries ICMJE||Canada|
|Removed Location Countries|
|NCT Number ICMJE||NCT00438425|
|Other Study ID Numbers ICMJE||REB 04-056c, CIHR RCT#: 68767|
|Has Data Monitoring Committee||No|
|Plan to Share Data||Not Provided|
|IPD Description||Not Provided|
|Responsible Party||David Jenkins, University of Toronto|
|Study Sponsor ICMJE||University of Toronto|
|Information Provided By||University of Toronto|
|Verification Date||December 2015|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP